Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

2016 Bonus Payments and 2017 Salary and Target Bonus Information
for Certain Executive Officers
On December 15, 2016, the Compensation Committee (the Committee)
of the Board of Directors of Bellicum Pharmaceuticals, Inc. (the
Company) approved (i) the payment of annual cash bonus awards
with respect to performance for fiscal year 2016, which will be
paid in January 2017, (ii) annual increases in base salaries for
fiscal year 2017, and (iii) target performance bonuses for fiscal
year 2017, for certain of the Companys executive officers as set
forth below. The base salaries for fiscal year 2017 are effective
as of January 1, 2017. The target performance bonus amounts for
fiscal year 2017 are expressed as a percentage of the
corresponding 2017 base salary and remain unchanged from 2016
target percentages.
The following table sets forth the amounts approved by the
Committee for each of the Companys principal executive officer,
principal financial officer and the other named executive
officers:
Name
Base Salary

2016 Bonus Payment
2017 Target Bonus
(% of Base Salary)
Thomas J. Farrell
President and Chief Executive Officer
$
516,133
$
177,891
50%
Annemarie Moseley, Ph.D., M.D.
Chief Operating Officer and Executive Vice President of
Clinical Development
$
435,000
$
119,934
40%
Alan A. Musso, CPA, CMA
Chief Financial Officer and Treasurer
$
385,000
$
91,448
35%
Equity Award Information for Certain Executive Officers
On December 15, 2016, the Committee also approved restricted
stock unit awards and stock option grants, effective as of
January 3, 2016, under the Companys 2014 Equity Incentive Plan
(the Plan), to the Companys principal executive officer,
principal financial officer and the other named executive
officer, as follows:
Name
Restricted Stock Unit Award (# of shares)
Option Award (# shares)
Thomas J. Farrell
President and Chief Executive Officer
26,875
48,375
Annemarie Moseley, Ph.D., M.D.
Chief Operating Officer and Executive Vice President of
Clinical Development
10,000
18,000
Alan A. Musso, CPA, CMA
Chief Financial Officer and Treasurer
7,500
13,500
The above restricted stock unit awards will vest annually over a
four-year period, commencing on the one-year anniversary of the
grant date, subject to the officers continued service to the
Company over the term of the vesting.
The above stock options will have an exercise price equal to the
closing price of the Companys common stock on the date of grant,
January 3, 2016, and vest over a four-year period. The stock
options entitle the holder, following vesting of the stock
option, to acquire the underlying number of shares by paying the
exercise price for such shares. The stock options will terminate
after 10 years, or earlier if the executive officer ceases to
provide services to the Company.
The Committee intends to grant additional stock options to the
officers in June 2017, contingent upon stockholder approval of an
increase in the available share reserve under the Plan.
Item 8.01 Other Events.
On December 21, 2016, the Committee approved an amendment to the
Companys non-employee director compensation policy to provide
that directors who are not also serving as an employee of the
Company will receive the compensation described in the policy,
even if serving as a consultant to the Company; and to include in
the policy the previously reported compensation for members of
the Companys Science Committee and Finance Committee. A copy of
the policy, as amended, is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Non-employee Director Compensation Policy


About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Recent Trading Information

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) closed its last trading session down -0.42 at 13.96 with 397,239 shares trading hands.